Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Toward a Neurobiological Model of Gestalt Confluence: Thalamocortical Integration as a Hypothetical Framework for Contact Interruption.

Brain sciences·2026
Same author

Self-Reported and Biologic Assessments of Prenatal Cannabis Use: Ancillary Analysis of a Prospective Observational Cohort.

Substance use & addiction journal·2025
Same author

Prenatal Cannabis Use and Depressive Symptoms.

Obstetrics and gynecology·2025
Same author

An Educational Assessment of Evidence Used for Variant Classification: A Report of the Association for Molecular Pathology.

The Journal of molecular diagnostics : JMD·2022
Same author

Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG).

Genetics in medicine : official journal of the American College of Medical Genetics·2022
Same author

The Science and Art of Clinical Genetic Variant Classification and Its Impact on Test Accuracy.

Annual review of genomics and human genetics·2021
Same journal

Advances in Hemostasis Laboratory Testing.

Clinics in laboratory medicine·2026
Same journal

Extracellular Vesicles in Hemostasis.

Clinics in laboratory medicine·2026
Same journal

Thrombin Generation Assay: Ready for Prime Time.

Clinics in laboratory medicine·2026
Same journal

Viscoelastic Testing for the Laboratorian: Recent Advances and Practical Advice.

Clinics in laboratory medicine·2026
Same journal

Practical Recommendations for Harmonization of Hemostasis Testing Across Hospital Sites.

Clinics in laboratory medicine·2026
Same journal

The Role of Hypoxia in Vascular Endothelial Dysfunction and Venous Thromboembolism.

Clinics in laboratory medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Pharmacogenetic testing for warfarin sensitivity.

Elaine Lyon1, Gwen McMillin, Roberta Melis

  • 1Department of Pathology, University of Utah, Salt Lake City, Utah, USA. lyone@aruplab.com

Clinics in Laboratory Medicine
|December 9, 2008
PubMed
Summary
This summary is machine-generated.

Genetic testing for warfarin sensitivity is now recommended by the FDA. This article reviews available genetic variants, testing technologies, and laboratory considerations for implementing warfarin pharmacogenetic assays.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Experiment Videos

Last Updated: Jun 27, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Area of Science:

  • Pharmacogenomics
  • Clinical Laboratory Science
  • Molecular Diagnostics

Background:

  • The US Food and Drug Administration (FDA) updated warfarin labeling to include genetic testing for warfarin sensitivity.
  • This change necessitates the development and implementation of pharmacogenetic testing in clinical laboratories.

Purpose of the Study:

  • To describe available genetic variants relevant to warfarin sensitivity.
  • To compare current technologies and assays for warfarin pharmacogenetic testing.
  • To discuss laboratory and service considerations for implementing these tests.

Main Methods:

  • Review of genetic variants associated with warfarin metabolism and response.
  • Comparison of different genotyping technologies and commercially available assays.
  • Discussion of laboratory operational aspects including quality control, proficiency testing, and turnaround times.

Main Results:

  • Specific genetic variants (e.g., VKORC1, CYP2C9) influencing warfarin pharmacokinetics and pharmacodynamics are identified.
  • Various molecular assay platforms are available, each with distinct advantages and limitations.
  • Key laboratory considerations include assay validation, quality assurance, and workflow optimization.

Conclusions:

  • The integration of genetic testing into warfarin therapy is becoming standard practice.
  • Laboratories must carefully select appropriate testing methodologies and establish robust operational procedures.
  • Successful implementation requires attention to both technical assay performance and clinical service delivery.